Menu Search
Equities

QUIA PHARMA AB (publ)

99B0:STU

QUIA PHARMA AB (publ)

Actions
  • Price (EUR)0.0016
  • Today's Change0.000 / 14.29%
  • Shares traded0.00
  • 1 Year change-92.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 05 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

QuiaPEG Pharmaceuticals Holding AB is a Sweden-based biotechnology company. The Company develops improved versions of clinically validated biopharmaceutical drugs based on PEGylation technology platform. The Company’s technology is applicable on proteins, peptides and small molecules and offers a half-life extension platform consisting of covalent, as well as extended release PEGylation. The Company focuses on development of long-acting biopharmaceuticals for the treatment of metabolic disorders. The main project intends to reduce the frequent injection therapy by requiring significantly fewer injections. The Company offers out-licensing and partnering opportunities. It has a patent portfolio with patents pending and an approved the United States patent covering chemical linkers.

  • Revenue in SEK (TTM)2.36m
  • Net income in SEK-13.86m
  • Incorporated2004
  • Employees8.00
  • Location
    QUIA PHARMA AB (publ)Uppsala Business ParkVirdings Alle 32 BUPPSALA 754 50SwedenSWE
  • Phone+46 87780006
  • Fax+46 87780005
  • Websitehttps://www.quiapeg.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.